AltruBio Inc.

Quick facts

Phase 2 pipeline

• ALTB-268 · Oncology
  ALTB-268 is a small molecule inhibitor of the CD47/SIRPα axis.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• AltruBio Inc. portfolio CI brief
• AltruBio Inc. pipeline updates RSS